Friday, June 3, 2011

AcelRx Army grant validates technology - CEO

AcelRx Pharmaceuticals Inc. has received a $5.6 million grant from the U.S. Army Medical Research and Material Command to fund its Phase 2 clinical trials for a new drug that has the potential to help wounded soldiers in the battlefield.
Its product, ARX-04, is a nanotablet dispensed under the tongue for non-invasive, rapid treatment of moderate to severe acute pain. The product also has uses for the general public to treat trauma or injury such as post-operative pain from knee replacement surgery.

No comments:

Post a Comment